Compounds > 3-(6-amino-5-(3,4,5-trimethoxyphenyl)pyridin-3-yl)phenol
Page last updated: 2024-11-13

3-(6-amino-5-(3,4,5-trimethoxyphenyl)pyridin-3-yl)phenol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

3-(6-amino-5-(3,4,5-trimethoxyphenyl)pyridin-3-yl)phenol: inhibits ALK2 protein; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID46173038
CHEMBL ID1230714
SCHEMBL ID16026073
MeSH IDM0588979

Synonyms (32)

Synonym
CHEMBL1230714
3-[6-amino-5-(3,4,5-trimethoxyphenyl)pyridin-3-yl]phenol
A3F ,
S7359 ,
1431985-92-0
FD5034
k 02288
k02288a
bdbm102619
CS-3395
SCHEMBL16026073
k02288 ,
k 02288a
3-[(6-amino-5-(3,4,5-trimethoxyphenyl)-3-pyridinyl]phenol
3-(6-amino-5-(3,4,5-trimethoxyphenyl)pyridin-3-yl)phenol
AC-31394
HY-12278
AKOS024458450
mfcd26936347
k-02288
phenol, 3-[6-amino-5-(3,4,5-trimethoxyphenyl)-3-pyridinyl]-
HMS3653M16
k02288, >98% (hplc)
NCGC00379244-09
SW220200-1
FT-0768190
EX-A2085
AS-16547
BCP09946
SB19486
CCG-268053
Q27457099

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019)		0.51
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (11)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
cytochrome P450 family 3 subfamily A polypeptide 4Homo sapiens (human)Potency4.77240.01237.983543.2770AID1645841
GVesicular stomatitis virusPotency0.84870.01238.964839.8107AID1645842
cytochrome P450 2D6Homo sapiens (human)Potency16.93300.00108.379861.1304AID1645840
Interferon betaHomo sapiens (human)Potency0.84870.00339.158239.8107AID1645842
HLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)Potency0.84870.01238.964839.8107AID1645842
Inositol hexakisphosphate kinase 1Homo sapiens (human)Potency0.84870.01238.964839.8107AID1645842
cytochrome P450 2C9, partialHomo sapiens (human)Potency0.84870.01238.964839.8107AID1645842
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Bone morphogenetic protein receptor type-1AHomo sapiens (human)IC50 (µMol)0.03430.00220.55684.2880AID1877424
TGF-beta receptor type-1Homo sapiens (human)IC50 (µMol)1.84000.00100.643610.0000AID1186981; AID1186984
Serine/threonine-protein kinase receptor R3Homo sapiens (human)IC50 (µMol)0.00180.00180.12150.8500AID1877422
Activin receptor type-1Homo sapiens (human)IC50 (µMol)0.01810.00100.72558.0380AID1186982; AID1877423
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (226)

Processvia Protein(s)Taxonomy
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell activation involved in immune responseInterferon betaHomo sapiens (human)
cell surface receptor signaling pathwayInterferon betaHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to virusInterferon betaHomo sapiens (human)
positive regulation of autophagyInterferon betaHomo sapiens (human)
cytokine-mediated signaling pathwayInterferon betaHomo sapiens (human)
natural killer cell activationInterferon betaHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT proteinInterferon betaHomo sapiens (human)
cellular response to interferon-betaInterferon betaHomo sapiens (human)
B cell proliferationInterferon betaHomo sapiens (human)
negative regulation of viral genome replicationInterferon betaHomo sapiens (human)
innate immune responseInterferon betaHomo sapiens (human)
positive regulation of innate immune responseInterferon betaHomo sapiens (human)
regulation of MHC class I biosynthetic processInterferon betaHomo sapiens (human)
negative regulation of T cell differentiationInterferon betaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIInterferon betaHomo sapiens (human)
defense response to virusInterferon betaHomo sapiens (human)
type I interferon-mediated signaling pathwayInterferon betaHomo sapiens (human)
neuron cellular homeostasisInterferon betaHomo sapiens (human)
cellular response to exogenous dsRNAInterferon betaHomo sapiens (human)
cellular response to virusInterferon betaHomo sapiens (human)
negative regulation of Lewy body formationInterferon betaHomo sapiens (human)
negative regulation of T-helper 2 cell cytokine productionInterferon betaHomo sapiens (human)
positive regulation of apoptotic signaling pathwayInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell differentiationInterferon betaHomo sapiens (human)
natural killer cell activation involved in immune responseInterferon betaHomo sapiens (human)
adaptive immune responseInterferon betaHomo sapiens (human)
T cell activation involved in immune responseInterferon betaHomo sapiens (human)
humoral immune responseInterferon betaHomo sapiens (human)
positive regulation of T cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
adaptive immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-independentHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of T cell anergyHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
defense responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
detection of bacteriumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-12 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-6 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protection from natural killer cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
innate immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of dendritic cell differentiationHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class IbHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of cardiac muscle cell apoptotic processBone morphogenetic protein receptor type-1AHomo sapiens (human)
regulation of neural crest cell differentiationBone morphogenetic protein receptor type-1AHomo sapiens (human)
positive regulation of gene expressionBone morphogenetic protein receptor type-1AHomo sapiens (human)
negative regulation of gene expressionBone morphogenetic protein receptor type-1AHomo sapiens (human)
positive regulation of transforming growth factor beta2 productionBone morphogenetic protein receptor type-1AHomo sapiens (human)
angiogenesisBone morphogenetic protein receptor type-1AHomo sapiens (human)
osteoblast differentiationBone morphogenetic protein receptor type-1AHomo sapiens (human)
in utero embryonic developmentBone morphogenetic protein receptor type-1AHomo sapiens (human)
mesoderm formationBone morphogenetic protein receptor type-1AHomo sapiens (human)
somitogenesisBone morphogenetic protein receptor type-1AHomo sapiens (human)
Mullerian duct regressionBone morphogenetic protein receptor type-1AHomo sapiens (human)
positive regulation of mesenchymal cell proliferationBone morphogenetic protein receptor type-1AHomo sapiens (human)
chondrocyte differentiationBone morphogenetic protein receptor type-1AHomo sapiens (human)
outflow tract septum morphogenesisBone morphogenetic protein receptor type-1AHomo sapiens (human)
outflow tract morphogenesisBone morphogenetic protein receptor type-1AHomo sapiens (human)
cardiac conduction system developmentBone morphogenetic protein receptor type-1AHomo sapiens (human)
atrioventricular valve developmentBone morphogenetic protein receptor type-1AHomo sapiens (human)
mitral valve morphogenesisBone morphogenetic protein receptor type-1AHomo sapiens (human)
tricuspid valve morphogenesisBone morphogenetic protein receptor type-1AHomo sapiens (human)
endocardial cushion morphogenesisBone morphogenetic protein receptor type-1AHomo sapiens (human)
cardiac right ventricle morphogenesisBone morphogenetic protein receptor type-1AHomo sapiens (human)
ventricular trabecula myocardium morphogenesisBone morphogenetic protein receptor type-1AHomo sapiens (human)
ventricular compact myocardium morphogenesisBone morphogenetic protein receptor type-1AHomo sapiens (human)
endocardial cushion formationBone morphogenetic protein receptor type-1AHomo sapiens (human)
immune responseBone morphogenetic protein receptor type-1AHomo sapiens (human)
transforming growth factor beta receptor signaling pathwayBone morphogenetic protein receptor type-1AHomo sapiens (human)
ectoderm developmentBone morphogenetic protein receptor type-1AHomo sapiens (human)
dorsal/ventral axis specificationBone morphogenetic protein receptor type-1AHomo sapiens (human)
neural crest cell developmentBone morphogenetic protein receptor type-1AHomo sapiens (human)
negative regulation of smooth muscle cell migrationBone morphogenetic protein receptor type-1AHomo sapiens (human)
central nervous system neuron differentiationBone morphogenetic protein receptor type-1AHomo sapiens (human)
pituitary gland developmentBone morphogenetic protein receptor type-1AHomo sapiens (human)
neural plate mediolateral regionalizationBone morphogenetic protein receptor type-1AHomo sapiens (human)
lung developmentBone morphogenetic protein receptor type-1AHomo sapiens (human)
positive regulation of bone mineralizationBone morphogenetic protein receptor type-1AHomo sapiens (human)
BMP signaling pathwayBone morphogenetic protein receptor type-1AHomo sapiens (human)
somatic stem cell population maintenanceBone morphogenetic protein receptor type-1AHomo sapiens (human)
hindlimb morphogenesisBone morphogenetic protein receptor type-1AHomo sapiens (human)
dorsal aorta morphogenesisBone morphogenetic protein receptor type-1AHomo sapiens (human)
odontogenesis of dentin-containing toothBone morphogenetic protein receptor type-1AHomo sapiens (human)
embryonic digit morphogenesisBone morphogenetic protein receptor type-1AHomo sapiens (human)
positive regulation of osteoblast differentiationBone morphogenetic protein receptor type-1AHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIBone morphogenetic protein receptor type-1AHomo sapiens (human)
paraxial mesoderm structural organizationBone morphogenetic protein receptor type-1AHomo sapiens (human)
lateral mesoderm developmentBone morphogenetic protein receptor type-1AHomo sapiens (human)
regulation of lateral mesodermal cell fate specificationBone morphogenetic protein receptor type-1AHomo sapiens (human)
mesendoderm developmentBone morphogenetic protein receptor type-1AHomo sapiens (human)
embryonic organ developmentBone morphogenetic protein receptor type-1AHomo sapiens (human)
developmental growthBone morphogenetic protein receptor type-1AHomo sapiens (human)
epithelial cell proliferationBone morphogenetic protein receptor type-1AHomo sapiens (human)
positive regulation of epithelial cell proliferationBone morphogenetic protein receptor type-1AHomo sapiens (human)
negative regulation of neurogenesisBone morphogenetic protein receptor type-1AHomo sapiens (human)
negative regulation of muscle cell differentiationBone morphogenetic protein receptor type-1AHomo sapiens (human)
roof of mouth developmentBone morphogenetic protein receptor type-1AHomo sapiens (human)
regulation of cardiac muscle cell proliferationBone morphogenetic protein receptor type-1AHomo sapiens (human)
positive regulation of cardiac muscle cell proliferationBone morphogenetic protein receptor type-1AHomo sapiens (human)
positive regulation of SMAD protein signal transductionBone morphogenetic protein receptor type-1AHomo sapiens (human)
ventricular septum morphogenesisBone morphogenetic protein receptor type-1AHomo sapiens (human)
heart formationBone morphogenetic protein receptor type-1AHomo sapiens (human)
atrioventricular node cell developmentBone morphogenetic protein receptor type-1AHomo sapiens (human)
pharyngeal arch artery morphogenesisBone morphogenetic protein receptor type-1AHomo sapiens (human)
cellular response to BMP stimulusBone morphogenetic protein receptor type-1AHomo sapiens (human)
positive regulation of miRNA transcriptionBone morphogenetic protein receptor type-1AHomo sapiens (human)
positive regulation of cardiac ventricle developmentBone morphogenetic protein receptor type-1AHomo sapiens (human)
positive regulation of vascular associated smooth muscle cell proliferationBone morphogenetic protein receptor type-1AHomo sapiens (human)
fibrous ring of heart morphogenesisBone morphogenetic protein receptor type-1AHomo sapiens (human)
regulation of cellular senescenceBone morphogenetic protein receptor type-1AHomo sapiens (human)
protein phosphorylationBone morphogenetic protein receptor type-1AHomo sapiens (human)
dorsal/ventral pattern formationBone morphogenetic protein receptor type-1AHomo sapiens (human)
cellular response to growth factor stimulusBone morphogenetic protein receptor type-1AHomo sapiens (human)
proepicardium developmentTGF-beta receptor type-1Homo sapiens (human)
negative regulation of cell migrationTGF-beta receptor type-1Homo sapiens (human)
positive regulation of extracellular matrix assemblyTGF-beta receptor type-1Homo sapiens (human)
skeletal system developmentTGF-beta receptor type-1Homo sapiens (human)
in utero embryonic developmentTGF-beta receptor type-1Homo sapiens (human)
kidney developmentTGF-beta receptor type-1Homo sapiens (human)
blastocyst developmentTGF-beta receptor type-1Homo sapiens (human)
epithelial to mesenchymal transitionTGF-beta receptor type-1Homo sapiens (human)
endothelial cell proliferationTGF-beta receptor type-1Homo sapiens (human)
negative regulation of endothelial cell proliferationTGF-beta receptor type-1Homo sapiens (human)
positive regulation of endothelial cell proliferationTGF-beta receptor type-1Homo sapiens (human)
lens development in camera-type eyeTGF-beta receptor type-1Homo sapiens (human)
ventricular trabecula myocardium morphogenesisTGF-beta receptor type-1Homo sapiens (human)
ventricular compact myocardium morphogenesisTGF-beta receptor type-1Homo sapiens (human)
regulation of DNA-templated transcriptionTGF-beta receptor type-1Homo sapiens (human)
apoptotic processTGF-beta receptor type-1Homo sapiens (human)
signal transductionTGF-beta receptor type-1Homo sapiens (human)
transforming growth factor beta receptor signaling pathwayTGF-beta receptor type-1Homo sapiens (human)
heart developmentTGF-beta receptor type-1Homo sapiens (human)
positive regulation of cell population proliferationTGF-beta receptor type-1Homo sapiens (human)
germ cell migrationTGF-beta receptor type-1Homo sapiens (human)
male gonad developmentTGF-beta receptor type-1Homo sapiens (human)
post-embryonic developmentTGF-beta receptor type-1Homo sapiens (human)
anterior/posterior pattern specificationTGF-beta receptor type-1Homo sapiens (human)
positive regulation of gene expressionTGF-beta receptor type-1Homo sapiens (human)
regulation of epithelial to mesenchymal transitionTGF-beta receptor type-1Homo sapiens (human)
positive regulation of epithelial to mesenchymal transitionTGF-beta receptor type-1Homo sapiens (human)
peptidyl-serine phosphorylationTGF-beta receptor type-1Homo sapiens (human)
collagen fibril organizationTGF-beta receptor type-1Homo sapiens (human)
positive regulation of cell growthTGF-beta receptor type-1Homo sapiens (human)
positive regulation of cell migrationTGF-beta receptor type-1Homo sapiens (human)
regulation of protein ubiquitinationTGF-beta receptor type-1Homo sapiens (human)
negative regulation of chondrocyte differentiationTGF-beta receptor type-1Homo sapiens (human)
activin receptor signaling pathwayTGF-beta receptor type-1Homo sapiens (human)
intracellular signal transductionTGF-beta receptor type-1Homo sapiens (human)
myofibroblast differentiationTGF-beta receptor type-1Homo sapiens (human)
wound healingTGF-beta receptor type-1Homo sapiens (human)
endothelial cell activationTGF-beta receptor type-1Homo sapiens (human)
extracellular structure organizationTGF-beta receptor type-1Homo sapiens (human)
endothelial cell migrationTGF-beta receptor type-1Homo sapiens (human)
positive regulation of DNA-templated transcriptionTGF-beta receptor type-1Homo sapiens (human)
filopodium assemblyTGF-beta receptor type-1Homo sapiens (human)
thymus developmentTGF-beta receptor type-1Homo sapiens (human)
neuron fate commitmentTGF-beta receptor type-1Homo sapiens (human)
embryonic cranial skeleton morphogenesisTGF-beta receptor type-1Homo sapiens (human)
skeletal system morphogenesisTGF-beta receptor type-1Homo sapiens (human)
mesenchymal cell differentiationTGF-beta receptor type-1Homo sapiens (human)
artery morphogenesisTGF-beta receptor type-1Homo sapiens (human)
cell motilityTGF-beta receptor type-1Homo sapiens (human)
positive regulation of filopodium assemblyTGF-beta receptor type-1Homo sapiens (human)
positive regulation of stress fiber assemblyTGF-beta receptor type-1Homo sapiens (human)
regulation of cell cycleTGF-beta receptor type-1Homo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionTGF-beta receptor type-1Homo sapiens (human)
parathyroid gland developmentTGF-beta receptor type-1Homo sapiens (human)
roof of mouth developmentTGF-beta receptor type-1Homo sapiens (human)
pharyngeal system developmentTGF-beta receptor type-1Homo sapiens (human)
regulation of cardiac muscle cell proliferationTGF-beta receptor type-1Homo sapiens (human)
cardiac epithelial to mesenchymal transitionTGF-beta receptor type-1Homo sapiens (human)
positive regulation of SMAD protein signal transductionTGF-beta receptor type-1Homo sapiens (human)
ventricular septum morphogenesisTGF-beta receptor type-1Homo sapiens (human)
angiogenesis involved in coronary vascular morphogenesisTGF-beta receptor type-1Homo sapiens (human)
coronary artery morphogenesisTGF-beta receptor type-1Homo sapiens (human)
response to cholesterolTGF-beta receptor type-1Homo sapiens (human)
cellular response to transforming growth factor beta stimulusTGF-beta receptor type-1Homo sapiens (human)
positive regulation of mesenchymal stem cell proliferationTGF-beta receptor type-1Homo sapiens (human)
positive regulation of vasculature developmentTGF-beta receptor type-1Homo sapiens (human)
positive regulation of epithelial to mesenchymal transition involved in endocardial cushion formationTGF-beta receptor type-1Homo sapiens (human)
positive regulation of tight junction disassemblyTGF-beta receptor type-1Homo sapiens (human)
epicardium morphogenesisTGF-beta receptor type-1Homo sapiens (human)
positive regulation of apoptotic signaling pathwayTGF-beta receptor type-1Homo sapiens (human)
negative regulation of extrinsic apoptotic signaling pathwayTGF-beta receptor type-1Homo sapiens (human)
protein phosphorylationTGF-beta receptor type-1Homo sapiens (human)
cellular response to growth factor stimulusTGF-beta receptor type-1Homo sapiens (human)
nervous system developmentTGF-beta receptor type-1Homo sapiens (human)
endocardial cushion to mesenchymal transitionSerine/threonine-protein kinase receptor R3Homo sapiens (human)
positive regulation of epithelial cell differentiationSerine/threonine-protein kinase receptor R3Homo sapiens (human)
positive regulation of Notch signaling pathwaySerine/threonine-protein kinase receptor R3Homo sapiens (human)
angiogenesisSerine/threonine-protein kinase receptor R3Homo sapiens (human)
response to hypoxiaSerine/threonine-protein kinase receptor R3Homo sapiens (human)
in utero embryonic developmentSerine/threonine-protein kinase receptor R3Homo sapiens (human)
regulation of endothelial cell proliferationSerine/threonine-protein kinase receptor R3Homo sapiens (human)
negative regulation of endothelial cell proliferationSerine/threonine-protein kinase receptor R3Homo sapiens (human)
positive regulation of endothelial cell proliferationSerine/threonine-protein kinase receptor R3Homo sapiens (human)
lymphangiogenesisSerine/threonine-protein kinase receptor R3Homo sapiens (human)
blood vessel maturationSerine/threonine-protein kinase receptor R3Homo sapiens (human)
blood vessel remodelingSerine/threonine-protein kinase receptor R3Homo sapiens (human)
blood vessel endothelial cell proliferation involved in sprouting angiogenesisSerine/threonine-protein kinase receptor R3Homo sapiens (human)
endocardial cushion morphogenesisSerine/threonine-protein kinase receptor R3Homo sapiens (human)
regulation of DNA replicationSerine/threonine-protein kinase receptor R3Homo sapiens (human)
regulation of DNA-templated transcriptionSerine/threonine-protein kinase receptor R3Homo sapiens (human)
negative regulation of cell adhesionSerine/threonine-protein kinase receptor R3Homo sapiens (human)
signal transductionSerine/threonine-protein kinase receptor R3Homo sapiens (human)
transforming growth factor beta receptor signaling pathwaySerine/threonine-protein kinase receptor R3Homo sapiens (human)
blood circulationSerine/threonine-protein kinase receptor R3Homo sapiens (human)
regulation of blood pressureSerine/threonine-protein kinase receptor R3Homo sapiens (human)
negative regulation of cell population proliferationSerine/threonine-protein kinase receptor R3Homo sapiens (human)
negative regulation of endothelial cell migrationSerine/threonine-protein kinase receptor R3Homo sapiens (human)
negative regulation of gene expressionSerine/threonine-protein kinase receptor R3Homo sapiens (human)
negative regulation of cell growthSerine/threonine-protein kinase receptor R3Homo sapiens (human)
negative regulation of cell migrationSerine/threonine-protein kinase receptor R3Homo sapiens (human)
BMP signaling pathwaySerine/threonine-protein kinase receptor R3Homo sapiens (human)
positive regulation of BMP signaling pathwaySerine/threonine-protein kinase receptor R3Homo sapiens (human)
positive regulation of chondrocyte differentiationSerine/threonine-protein kinase receptor R3Homo sapiens (human)
activin receptor signaling pathwaySerine/threonine-protein kinase receptor R3Homo sapiens (human)
wound healing, spreading of epidermal cellsSerine/threonine-protein kinase receptor R3Homo sapiens (human)
dorsal aorta morphogenesisSerine/threonine-protein kinase receptor R3Homo sapiens (human)
regulation of blood vessel endothelial cell migrationSerine/threonine-protein kinase receptor R3Homo sapiens (human)
negative regulation of blood vessel endothelial cell migrationSerine/threonine-protein kinase receptor R3Homo sapiens (human)
negative regulation of endothelial cell differentiationSerine/threonine-protein kinase receptor R3Homo sapiens (human)
positive regulation of endothelial cell differentiationSerine/threonine-protein kinase receptor R3Homo sapiens (human)
positive regulation of angiogenesisSerine/threonine-protein kinase receptor R3Homo sapiens (human)
positive regulation of DNA-templated transcriptionSerine/threonine-protein kinase receptor R3Homo sapiens (human)
positive regulation of transcription by RNA polymerase IISerine/threonine-protein kinase receptor R3Homo sapiens (human)
negative regulation of focal adhesion assemblySerine/threonine-protein kinase receptor R3Homo sapiens (human)
positive regulation of SMAD protein signal transductionSerine/threonine-protein kinase receptor R3Homo sapiens (human)
lymphatic endothelial cell differentiationSerine/threonine-protein kinase receptor R3Homo sapiens (human)
artery developmentSerine/threonine-protein kinase receptor R3Homo sapiens (human)
venous blood vessel developmentSerine/threonine-protein kinase receptor R3Homo sapiens (human)
endothelial tube morphogenesisSerine/threonine-protein kinase receptor R3Homo sapiens (human)
retina vasculature development in camera-type eyeSerine/threonine-protein kinase receptor R3Homo sapiens (human)
cellular response to transforming growth factor beta stimulusSerine/threonine-protein kinase receptor R3Homo sapiens (human)
cellular response to BMP stimulusSerine/threonine-protein kinase receptor R3Homo sapiens (human)
positive regulation of bicellular tight junction assemblySerine/threonine-protein kinase receptor R3Homo sapiens (human)
protein phosphorylationSerine/threonine-protein kinase receptor R3Homo sapiens (human)
dorsal/ventral pattern formationSerine/threonine-protein kinase receptor R3Homo sapiens (human)
heart developmentSerine/threonine-protein kinase receptor R3Homo sapiens (human)
cellular response to growth factor stimulusSerine/threonine-protein kinase receptor R3Homo sapiens (human)
outflow tract septum morphogenesisActivin receptor type-1Homo sapiens (human)
branching involved in blood vessel morphogenesisActivin receptor type-1Homo sapiens (human)
in utero embryonic developmentActivin receptor type-1Homo sapiens (human)
gastrulation with mouth forming secondActivin receptor type-1Homo sapiens (human)
mesoderm formationActivin receptor type-1Homo sapiens (human)
neural crest cell migrationActivin receptor type-1Homo sapiens (human)
acute inflammatory responseActivin receptor type-1Homo sapiens (human)
embryonic heart tube morphogenesisActivin receptor type-1Homo sapiens (human)
atrioventricular valve morphogenesisActivin receptor type-1Homo sapiens (human)
mitral valve morphogenesisActivin receptor type-1Homo sapiens (human)
endocardial cushion formationActivin receptor type-1Homo sapiens (human)
endocardial cushion fusionActivin receptor type-1Homo sapiens (human)
atrial septum primum morphogenesisActivin receptor type-1Homo sapiens (human)
transforming growth factor beta receptor signaling pathwayActivin receptor type-1Homo sapiens (human)
germ cell developmentActivin receptor type-1Homo sapiens (human)
determination of left/right symmetryActivin receptor type-1Homo sapiens (human)
negative regulation of signal transductionActivin receptor type-1Homo sapiens (human)
regulation of ossificationActivin receptor type-1Homo sapiens (human)
positive regulation of cell migrationActivin receptor type-1Homo sapiens (human)
positive regulation of bone mineralizationActivin receptor type-1Homo sapiens (human)
BMP signaling pathwayActivin receptor type-1Homo sapiens (human)
activin receptor signaling pathwayActivin receptor type-1Homo sapiens (human)
negative regulation of activin receptor signaling pathwayActivin receptor type-1Homo sapiens (human)
positive regulation of osteoblast differentiationActivin receptor type-1Homo sapiens (human)
positive regulation of DNA-templated transcriptionActivin receptor type-1Homo sapiens (human)
positive regulation of transcription by RNA polymerase IIActivin receptor type-1Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationActivin receptor type-1Homo sapiens (human)
smooth muscle cell differentiationActivin receptor type-1Homo sapiens (human)
pharyngeal system developmentActivin receptor type-1Homo sapiens (human)
positive regulation of SMAD protein signal transductionActivin receptor type-1Homo sapiens (human)
ventricular septum morphogenesisActivin receptor type-1Homo sapiens (human)
cardiac muscle cell fate commitmentActivin receptor type-1Homo sapiens (human)
endocardial cushion cell fate commitmentActivin receptor type-1Homo sapiens (human)
positive regulation of cardiac epithelial to mesenchymal transitionActivin receptor type-1Homo sapiens (human)
cellular response to BMP stimulusActivin receptor type-1Homo sapiens (human)
positive regulation of determination of dorsal identityActivin receptor type-1Homo sapiens (human)
negative regulation of G1/S transition of mitotic cell cycleActivin receptor type-1Homo sapiens (human)
negative regulation of extrinsic apoptotic signaling pathwayActivin receptor type-1Homo sapiens (human)
dorsal/ventral pattern formationActivin receptor type-1Homo sapiens (human)
heart developmentActivin receptor type-1Homo sapiens (human)
protein phosphorylationActivin receptor type-1Homo sapiens (human)
cellular response to growth factor stimulusActivin receptor type-1Homo sapiens (human)
inositol phosphate metabolic processInositol hexakisphosphate kinase 1Homo sapiens (human)
phosphatidylinositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
negative regulation of cold-induced thermogenesisInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (39)

Processvia Protein(s)Taxonomy
cytokine activityInterferon betaHomo sapiens (human)
cytokine receptor bindingInterferon betaHomo sapiens (human)
type I interferon receptor bindingInterferon betaHomo sapiens (human)
protein bindingInterferon betaHomo sapiens (human)
chloramphenicol O-acetyltransferase activityInterferon betaHomo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
signaling receptor bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
peptide antigen bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein-folding chaperone bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein serine/threonine kinase activityBone morphogenetic protein receptor type-1AHomo sapiens (human)
transmembrane receptor protein serine/threonine kinase activityBone morphogenetic protein receptor type-1AHomo sapiens (human)
transforming growth factor beta receptor activity, type IBone morphogenetic protein receptor type-1AHomo sapiens (human)
protein bindingBone morphogenetic protein receptor type-1AHomo sapiens (human)
ATP bindingBone morphogenetic protein receptor type-1AHomo sapiens (human)
BMP bindingBone morphogenetic protein receptor type-1AHomo sapiens (human)
protein homodimerization activityBone morphogenetic protein receptor type-1AHomo sapiens (human)
SMAD bindingBone morphogenetic protein receptor type-1AHomo sapiens (human)
metal ion bindingBone morphogenetic protein receptor type-1AHomo sapiens (human)
BMP receptor activityBone morphogenetic protein receptor type-1AHomo sapiens (human)
transforming growth factor beta receptor activityTGF-beta receptor type-1Homo sapiens (human)
growth factor bindingTGF-beta receptor type-1Homo sapiens (human)
transforming growth factor beta bindingTGF-beta receptor type-1Homo sapiens (human)
protein kinase activityTGF-beta receptor type-1Homo sapiens (human)
protein serine/threonine kinase activityTGF-beta receptor type-1Homo sapiens (human)
transmembrane receptor protein serine/threonine kinase activityTGF-beta receptor type-1Homo sapiens (human)
transforming growth factor beta receptor activityTGF-beta receptor type-1Homo sapiens (human)
transforming growth factor beta receptor activity, type ITGF-beta receptor type-1Homo sapiens (human)
type II transforming growth factor beta receptor bindingTGF-beta receptor type-1Homo sapiens (human)
protein bindingTGF-beta receptor type-1Homo sapiens (human)
ATP bindingTGF-beta receptor type-1Homo sapiens (human)
ubiquitin protein ligase bindingTGF-beta receptor type-1Homo sapiens (human)
SMAD bindingTGF-beta receptor type-1Homo sapiens (human)
metal ion bindingTGF-beta receptor type-1Homo sapiens (human)
transforming growth factor beta bindingTGF-beta receptor type-1Homo sapiens (human)
I-SMAD bindingTGF-beta receptor type-1Homo sapiens (human)
activin receptor activity, type ITGF-beta receptor type-1Homo sapiens (human)
activin bindingTGF-beta receptor type-1Homo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase receptor R3Homo sapiens (human)
transmembrane receptor protein serine/threonine kinase activitySerine/threonine-protein kinase receptor R3Homo sapiens (human)
transforming growth factor beta receptor activitySerine/threonine-protein kinase receptor R3Homo sapiens (human)
transforming growth factor beta receptor activity, type ISerine/threonine-protein kinase receptor R3Homo sapiens (human)
protein bindingSerine/threonine-protein kinase receptor R3Homo sapiens (human)
ATP bindingSerine/threonine-protein kinase receptor R3Homo sapiens (human)
activin receptor activity, type ISerine/threonine-protein kinase receptor R3Homo sapiens (human)
protein kinase bindingSerine/threonine-protein kinase receptor R3Homo sapiens (human)
SMAD bindingSerine/threonine-protein kinase receptor R3Homo sapiens (human)
metal ion bindingSerine/threonine-protein kinase receptor R3Homo sapiens (human)
activin bindingSerine/threonine-protein kinase receptor R3Homo sapiens (human)
transforming growth factor beta bindingSerine/threonine-protein kinase receptor R3Homo sapiens (human)
BMP receptor activitySerine/threonine-protein kinase receptor R3Homo sapiens (human)
activin receptor activity, type IActivin receptor type-1Homo sapiens (human)
protein kinase activityActivin receptor type-1Homo sapiens (human)
protein serine/threonine kinase activityActivin receptor type-1Homo sapiens (human)
transmembrane receptor protein serine/threonine kinase activityActivin receptor type-1Homo sapiens (human)
protein bindingActivin receptor type-1Homo sapiens (human)
ATP bindingActivin receptor type-1Homo sapiens (human)
peptide hormone bindingActivin receptor type-1Homo sapiens (human)
protein homodimerization activityActivin receptor type-1Homo sapiens (human)
cadherin bindingActivin receptor type-1Homo sapiens (human)
SMAD bindingActivin receptor type-1Homo sapiens (human)
metal ion bindingActivin receptor type-1Homo sapiens (human)
activin bindingActivin receptor type-1Homo sapiens (human)
transforming growth factor beta bindingActivin receptor type-1Homo sapiens (human)
BMP receptor activityActivin receptor type-1Homo sapiens (human)
protein tyrosine kinase bindingActivin receptor type-1Homo sapiens (human)
transforming growth factor beta receptor activity, type IActivin receptor type-1Homo sapiens (human)
inositol-1,3,4,5,6-pentakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol heptakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
protein bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
ATP bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 1-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 3-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol 5-diphosphate pentakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol diphosphate tetrakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (34)

Processvia Protein(s)Taxonomy
extracellular spaceInterferon betaHomo sapiens (human)
extracellular regionInterferon betaHomo sapiens (human)
Golgi membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
endoplasmic reticulumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
Golgi apparatusHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
cell surfaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
ER to Golgi transport vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
secretory granule membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
phagocytic vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
early endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
recycling endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular exosomeHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
lumenal side of endoplasmic reticulum membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
MHC class I protein complexHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular spaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
external side of plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
caveolaBone morphogenetic protein receptor type-1AHomo sapiens (human)
plasma membraneBone morphogenetic protein receptor type-1AHomo sapiens (human)
external side of plasma membraneBone morphogenetic protein receptor type-1AHomo sapiens (human)
membraneBone morphogenetic protein receptor type-1AHomo sapiens (human)
dendriteBone morphogenetic protein receptor type-1AHomo sapiens (human)
neuronal cell bodyBone morphogenetic protein receptor type-1AHomo sapiens (human)
HFE-transferrin receptor complexBone morphogenetic protein receptor type-1AHomo sapiens (human)
plasma membraneBone morphogenetic protein receptor type-1AHomo sapiens (human)
receptor complexBone morphogenetic protein receptor type-1AHomo sapiens (human)
nucleusTGF-beta receptor type-1Homo sapiens (human)
endosomeTGF-beta receptor type-1Homo sapiens (human)
plasma membraneTGF-beta receptor type-1Homo sapiens (human)
bicellular tight junctionTGF-beta receptor type-1Homo sapiens (human)
cell surfaceTGF-beta receptor type-1Homo sapiens (human)
membrane raftTGF-beta receptor type-1Homo sapiens (human)
transforming growth factor beta ligand-receptor complexTGF-beta receptor type-1Homo sapiens (human)
receptor complexTGF-beta receptor type-1Homo sapiens (human)
plasma membraneTGF-beta receptor type-1Homo sapiens (human)
activin receptor complexTGF-beta receptor type-1Homo sapiens (human)
plasma membraneSerine/threonine-protein kinase receptor R3Homo sapiens (human)
cell surfaceSerine/threonine-protein kinase receptor R3Homo sapiens (human)
dendriteSerine/threonine-protein kinase receptor R3Homo sapiens (human)
neuronal cell bodySerine/threonine-protein kinase receptor R3Homo sapiens (human)
plasma membraneSerine/threonine-protein kinase receptor R3Homo sapiens (human)
BMP receptor complexSerine/threonine-protein kinase receptor R3Homo sapiens (human)
plasma membraneActivin receptor type-1Homo sapiens (human)
apical part of cellActivin receptor type-1Homo sapiens (human)
activin receptor complexActivin receptor type-1Homo sapiens (human)
BMP receptor complexActivin receptor type-1Homo sapiens (human)
plasma membraneActivin receptor type-1Homo sapiens (human)
fibrillar centerInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
cytosolInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleusInositol hexakisphosphate kinase 1Homo sapiens (human)
cytoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (26)

Assay IDTitleYearJournalArticle
AID1186992Cytotoxicity against human HepG2 cells assessed as cell viability at 10 uM after 4 hrs by Cell-Titer Glo assay2014Journal of medicinal chemistry, Oct-09, Volume: 57, Issue:19
Structure-activity relationship of 3,5-diaryl-2-aminopyridine ALK2 inhibitors reveals unaltered binding affinity for fibrodysplasia ossificans progressiva causing mutants.
AID1698823Antimitotic activity against sea urchin embryo assessed as cleavage arrest measured 2.5 to 6 hrs post-fertilization by light microscopy analysis2020Bioorganic & medicinal chemistry letters, 12-01, Volume: 30, Issue:23
Computational modeling and target synthesis of monomethoxy-substituted o-diphenylisoxazoles with unexpectedly high antimitotic microtubule destabilizing activity.
AID1877424Inhibition of GST-tagged human recombinant ALK3 expressed in insect cells using casein as substrate in presence of [gamma-32P]ATP incubated for 45 mins by Microscint-20 scintillation counting analysis2022Bioorganic & medicinal chemistry letters, 01-01, Volume: 55Inhibition of ALK2 with bicyclic pyridyllactams.
AID1186996Cytotoxicity against human HepG2 cells assessed as cell viability at 100 uM after 24 hrs by Cell-Titer Glo assay2014Journal of medicinal chemistry, Oct-09, Volume: 57, Issue:19
Structure-activity relationship of 3,5-diaryl-2-aminopyridine ALK2 inhibitors reveals unaltered binding affinity for fibrodysplasia ossificans progressiva causing mutants.
AID1186991Cytotoxicity against human HepG2 cells assessed as cell viability at 1 uM after 4 hrs by Cell-Titer Glo assay2014Journal of medicinal chemistry, Oct-09, Volume: 57, Issue:19
Structure-activity relationship of 3,5-diaryl-2-aminopyridine ALK2 inhibitors reveals unaltered binding affinity for fibrodysplasia ossificans progressiva causing mutants.
AID1186989Inhibition of BMP2-induced BMP receptor type 1 ALK2 in mouse C2C12 cells after 30 mins by luciferase reporter gene assay2014Journal of medicinal chemistry, Oct-09, Volume: 57, Issue:19
Structure-activity relationship of 3,5-diaryl-2-aminopyridine ALK2 inhibitors reveals unaltered binding affinity for fibrodysplasia ossificans progressiva causing mutants.
AID1186995Cytotoxicity against human HepG2 cells assessed as cell viability at 10 uM after 24 hrs by Cell-Titer Glo assay2014Journal of medicinal chemistry, Oct-09, Volume: 57, Issue:19
Structure-activity relationship of 3,5-diaryl-2-aminopyridine ALK2 inhibitors reveals unaltered binding affinity for fibrodysplasia ossificans progressiva causing mutants.
AID1186985Selectivity ratio of IC50 for TGFbeta1-induced TGFbeta type 1 ALK5 in HEK293T cells to IC50 for BMP6-induced BMP receptor type 1 ALK2 in mouse C2C12 cells2014Journal of medicinal chemistry, Oct-09, Volume: 57, Issue:19
Structure-activity relationship of 3,5-diaryl-2-aminopyridine ALK2 inhibitors reveals unaltered binding affinity for fibrodysplasia ossificans progressiva causing mutants.
AID1186983Inhibition of BMP6-induced BMP receptor type 1 ALK2 in mouse C2C12 cells after 30 mins by luciferase reporter gene assay2014Journal of medicinal chemistry, Oct-09, Volume: 57, Issue:19
Structure-activity relationship of 3,5-diaryl-2-aminopyridine ALK2 inhibitors reveals unaltered binding affinity for fibrodysplasia ossificans progressiva causing mutants.
AID1186984Inhibition of TGFbeta1-induced TGFbeta type 1 ALK5 in HEK293T cells after 30 mins by luciferase reporter gene assay2014Journal of medicinal chemistry, Oct-09, Volume: 57, Issue:19
Structure-activity relationship of 3,5-diaryl-2-aminopyridine ALK2 inhibitors reveals unaltered binding affinity for fibrodysplasia ossificans progressiva causing mutants.
AID1698824Antimitotic activity against sea urchin embryo assessed as embryo spinning measured 2.5 to 6 hrs post-fertilization observed after 15 min to 20 hrs of treatment by light microscopy analysis2020Bioorganic & medicinal chemistry letters, 12-01, Volume: 30, Issue:23
Computational modeling and target synthesis of monomethoxy-substituted o-diphenylisoxazoles with unexpectedly high antimitotic microtubule destabilizing activity.
AID1186979Inhibition of purified human ALK2 kinase Q207D mutant (201-499 residues) by RT-PCR analysis2014Journal of medicinal chemistry, Oct-09, Volume: 57, Issue:19
Structure-activity relationship of 3,5-diaryl-2-aminopyridine ALK2 inhibitors reveals unaltered binding affinity for fibrodysplasia ossificans progressiva causing mutants.
AID1186990Inhibition of BMP4-induced BMP receptor in mouse C2C12 cells after 30 mins by luciferase reporter gene assay2014Journal of medicinal chemistry, Oct-09, Volume: 57, Issue:19
Structure-activity relationship of 3,5-diaryl-2-aminopyridine ALK2 inhibitors reveals unaltered binding affinity for fibrodysplasia ossificans progressiva causing mutants.
AID1186981Inhibition of purified human ALK5 kinase after 45 mins by liquid scintillation counting in presence of ATP [gamma-32P]2014Journal of medicinal chemistry, Oct-09, Volume: 57, Issue:19
Structure-activity relationship of 3,5-diaryl-2-aminopyridine ALK2 inhibitors reveals unaltered binding affinity for fibrodysplasia ossificans progressiva causing mutants.
AID1877422Inhibition of GST-tagged human recombinant ALK1 expressed in baculovirus expression system using casein as substrate in presence of [gamma-32P]ATP incubated for 45 mins by Microscint-20 scintillation counting analysis2022Bioorganic & medicinal chemistry letters, 01-01, Volume: 55Inhibition of ALK2 with bicyclic pyridyllactams.
AID1186980Inhibition of purified ALK5 kinase (unknown origin) by RT-PCR analysis2014Journal of medicinal chemistry, Oct-09, Volume: 57, Issue:19
Structure-activity relationship of 3,5-diaryl-2-aminopyridine ALK2 inhibitors reveals unaltered binding affinity for fibrodysplasia ossificans progressiva causing mutants.
AID1186994Cytotoxicity against human HepG2 cells assessed as cell viability at 1 uM after 24 hrs by Cell-Titer Glo assay2014Journal of medicinal chemistry, Oct-09, Volume: 57, Issue:19
Structure-activity relationship of 3,5-diaryl-2-aminopyridine ALK2 inhibitors reveals unaltered binding affinity for fibrodysplasia ossificans progressiva causing mutants.
AID1186982Inhibition of human recombinant human ALK2 kinase after 45 mins by liquid scintillation counting in presence of ATP [gamma-32P]2014Journal of medicinal chemistry, Oct-09, Volume: 57, Issue:19
Structure-activity relationship of 3,5-diaryl-2-aminopyridine ALK2 inhibitors reveals unaltered binding affinity for fibrodysplasia ossificans progressiva causing mutants.
AID1877423Inhibition of GST-tagged human recombinant ALK2 (145 to 509 residues) expressed in baculovirus expression system using casein as substrate in presence of [gamma-32P]ATP incubated for 45 mins by Microscint-20 scintillation counting analysis2022Bioorganic & medicinal chemistry letters, 01-01, Volume: 55Inhibition of ALK2 with bicyclic pyridyllactams.
AID1698822Antimitotic activity against sea urchin embryo assessed as cleavage alteration measured 2.5 to 6 hrs post-fertilization by light microscopy analysis2020Bioorganic & medicinal chemistry letters, 12-01, Volume: 30, Issue:23
Computational modeling and target synthesis of monomethoxy-substituted o-diphenylisoxazoles with unexpectedly high antimitotic microtubule destabilizing activity.
AID1186993Cytotoxicity against human HepG2 cells assessed as cell viability at 100 uM after 4 hrs by Cell-Titer Glo assay2014Journal of medicinal chemistry, Oct-09, Volume: 57, Issue:19
Structure-activity relationship of 3,5-diaryl-2-aminopyridine ALK2 inhibitors reveals unaltered binding affinity for fibrodysplasia ossificans progressiva causing mutants.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347159Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347160Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (12)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's7 (58.33)24.3611
2020's5 (41.67)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.97

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.97 (24.57)
Research Supply Index2.56 (2.92)
Research Growth Index4.54 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.97)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other12 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
imatinib
[no description available]		2.110aromatic amine;
benzamides;
N-methylpiperazine;
pyridines;
pyrimidines		antineoplastic agent;
apoptosis inducer;
tyrosine kinase inhibitor
colchicine
(S)-colchicine : A colchicine that has (S)-configuration. It is a secondary metabolite, has anti-inflammatory properties and is used to treat gout, crystal-induced joint inflammation, familial Mediterranean fever, and many other conditions.		2.2510alkaloid;
colchicine		anti-inflammatory agent;
gout suppressant;
mutagen
xanthenes
Xanthenes: Compounds with three aromatic rings in linear arrangement with an OXYGEN in the center ring.		2.1510xanthene
pyrroles
1H-pyrrole : A tautomer of pyrrole that has the double bonds at positions 2 and 4.. pyrrole : A five-membered monocyclic heteroarene comprising one NH and four CH units which forms the parent compound of the pyrrole group of compounds. Its five-membered ring structure has three tautomers. A 'closed class'.. azole : Any monocyclic heteroarene consisting of a five-membered ring containing nitrogen. Azoles can also contain one or more other non-carbon atoms, such as nitrogen, sulfur or oxygen.		2.1510pyrrole;
secondary amine
alpha-aminopyridine
alpha-aminopyridine: RN given refers to parent cpd; structure in Merck Index, 9th ed, #485. aminopyridine : Compounds containing a pyridine skeleton substituted by one or more amine groups.		3.5170
podophyllotoxin
Podophyllum: A genus of poisonous American herbs, family BERBERIDACEAE. The roots yield PODOPHYLLOTOXIN and other pharmacologically important agents. The plant was formerly used as a cholagogue and cathartic. It is different from the European mandrake, MANDRAGORA.		2.2510furonaphthodioxole;
lignan;
organic heterotetracyclic compound		antimitotic;
antineoplastic agent;
keratolytic drug;
microtubule-destabilising agent;
plant metabolite;
tubulin modulator
gefitinib
[no description available]		2.110aromatic ether;
monochlorobenzenes;
monofluorobenzenes;
morpholines;
quinazolines;
secondary amino compound;
tertiary amino compound		antineoplastic agent;
epidermal growth factor receptor antagonist
erlotinib
[no description available]		2.110aromatic ether;
quinazolines;
secondary amino compound;
terminal acetylenic compound		antineoplastic agent;
epidermal growth factor receptor antagonist;
protein kinase inhibitor
lapatinib
[no description available]		2.110furans;
organochlorine compound;
organofluorine compound;
quinazolines		antineoplastic agent;
tyrosine kinase inhibitor
sorafenib
[no description available]		2.110(trifluoromethyl)benzenes;
aromatic ether;
monochlorobenzenes;
phenylureas;
pyridinecarboxamide		angiogenesis inhibitor;
anticoronaviral agent;
antineoplastic agent;
EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor;
ferroptosis inducer;
tyrosine kinase inhibitor
repsox
RepSox: inhibits TGF-beta signaling; structure in first source appears to be incorrect		2.1510pyrazolopyridine
s 1033
[no description available]		2.110(trifluoromethyl)benzenes;
imidazoles;
pyridines;
pyrimidines;
secondary amino compound;
secondary carboxamide		anticoronaviral agent;
antineoplastic agent;
tyrosine kinase inhibitor
dasatinib
N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-yl)amino)-1,3-thiazole-5-carboxamide: a dasatinib prodrug; structure in first source. dasatinib (anhydrous) : An aminopyrimidine that is 2-methylpyrimidine which is substituted at position 4 by the primary amino group of 2-amino-1,3-thiazole-5-carboxylic acid and at position 6 by a 4-(2-hydroxyethyl)piperazin-1-yl group, and in which the carboxylic acid group has been formally condensed with 2-chloro-6-methylaniline to afford the corresponding amide. A multi-targeted kinase inhibitor, it is used, particularly as the monohydrate, for the treatment of chronic, accelerated, or myeloid or lymphoid blast phase chronic myeloid leukemia. Note that the name 'dasatinib' is used to refer to the monohydrate (USAN) as well as to anhydrous dasatinib (INN).		2.1101,3-thiazoles;
aminopyrimidine;
monocarboxylic acid amide;
N-(2-hydroxyethyl)piperazine;
N-arylpiperazine;
organochlorine compound;
secondary amino compound;
tertiary amino compound		anticoronaviral agent;
antineoplastic agent;
tyrosine kinase inhibitor
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1h-imidazol-2-yl)benzamide
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide: a TGF-beta type I receptor kinase activity inhibitor		2.2510benzamides;
benzodioxoles;
imidazoles;
pyridines		EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor
su 11248
[no description available]		2.110monocarboxylic acid amide;
pyrroles		angiogenesis inhibitor;
antineoplastic agent;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor;
immunomodulator;
neuroprotective agent;
vascular endothelial growth factor receptor antagonist
fosbretabulin
[no description available]		2.2510stilbenoid
staurosporine
staurosporinium : Conjugate acid of staurosporine.		2.1710ammonium ion derivative
pazopanib
pazopanib: a protein kinase inhibitor. pazopanib : A pyrimidine that is 5-(pyrimidin-2-yl}amino-2-methylbenzenesulfonamide substituted at position 4 by a (2,3-dimethylindazol-6-yl)(methyl)amino group. Used as its hydrochloride salt for treatment of kidney cancer.		2.110aminopyrimidine;
indazoles;
sulfonamide		angiogenesis modulating agent;
antineoplastic agent;
tyrosine kinase inhibitor;
vascular endothelial growth factor receptor antagonist
dorsomorphin
dorsomorphin: an AMPK inhibitor. dorsomorphin : A pyrazolopyrimidine that is pyrazolo[1,5-a]pyrimidine which is substituted at positions 3 and 6 by pyridin-4-yl and p-[2-(piperidin-1-yl)ethoxy]phenyl groups, respectively. It is a potent, selective, reversible, and ATP-competitive inhibitor of AMPK (AMP-activated protein kinase, EC 2.7.11.31) and a selective inhibitor of bone morphogenetic protein (BMP) signaling.		2.1110aromatic ether;
piperidines;
pyrazolopyrimidine;
pyridines		bone morphogenetic protein receptor antagonist;
EC 2.7.11.31 {[hydroxymethylglutaryl-CoA reductase (NADPH)] kinase} inhibitor
crizotinib
Crizotinib: A piperidine and aminopyridine derivative that acts as an inhibitor of RECEPTOR PROTEIN-TYROSINE KINASES, including ANAPLASTIC LYMPHOMA KINASE (ALK) and HEPATOCYTE GROWTH FACTOR RECEPTOR (HGFR; c-Met). It is used in the treatment of NON-SMALL CELL LUNG CANCER.. crizotinib : A 3-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-[1-(piperidin-4-yl)pyrazol-4-yl]pyridin-2-amine that has R configuration at the chiral centre. The active enantiomer, it acts as a kinase inhibitor and is used for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC)		2.1103-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-[1-(piperidin-4-yl)pyrazol-4-yl]pyridin-2-amineantineoplastic agent;
biomarker;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor
ly2109761
[no description available]		2.1510
gdc 0449
HhAntag691: inhibits the hedgehog pathway and ABC transporters; has antineoplastic activity		2.1710benzamides;
monochlorobenzenes;
pyridines;
sulfone		antineoplastic agent;
Hedgehog signaling pathway inhibitor;
SMO receptor antagonist;
teratogenic agent
incb-018424
[no description available]		2.110nitrile;
pyrazoles;
pyrrolopyrimidine		antineoplastic agent;
EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor
ldn 193189
LDN 193189: inhibits bone morphogenetic protein signaling		2.4920pyrimidines
plx4032
[no description available]		2.110aromatic ketone;
difluorobenzene;
monochlorobenzenes;
pyrrolopyridine;
sulfonamide		antineoplastic agent;
B-Raf inhibitor
transforming growth factor beta
Transforming Growth Factor beta: A factor synthesized in a wide variety of tissues. It acts synergistically with TGF-alpha in inducing phenotypic transformation and can also act as a negative autocrine growth factor. TGF-beta has a potential role in embryonal development, cellular differentiation, hormone secretion, and immune function. TGF-beta is found mostly as homodimer forms of separate gene products TGF-beta1, TGF-beta2 or TGF-beta3. Heterodimers composed of TGF-beta1 and 2 (TGF-beta1.2) or of TGF-beta2 and 3 (TGF-beta2.3) have been isolated. The TGF-beta proteins are synthesized as precursor proteins.		2.1510
ldn-212854
[no description available]		2.110
debio 1347
CH5183284: a fibroblast growth factor receptor antagonist; structure in first source		2.1710
xav939
XAV939: selectively inhibits beta-catenin-mediated transcription; structure in first source. XAV939 : A thiopyranopyrimidine in which a 7,8-dihydro-5H-thiopyrano[4,3-d]pyrimidine skeleton is substituted at C-4 by a hydroxy group and at C-2 by a para-(trifluoromethyl)phenyl group.		2.1710(trifluoromethyl)benzenes;
thiopyranopyrimidine		tankyrase inhibitor
bms 536924
BMS 536924: inhibits insulin-like growth factor I receptor kinase; structure in first source		2.1710
ConditionIndicatedRelationship StrengthStudiesTrials
Fibrodysplasia Ossificans Progressiva
[description not available]		02.110
Myositis Ossificans
A disease characterized by bony deposits or the ossification of muscle tissue.		02.110
Congenital Zika Syndrome
[description not available]		02.2510
Disease Models, Animal
Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.		02.2510
Zika Virus Infection
A viral disease transmitted by the bite of AEDES mosquitoes infected with ZIKA VIRUS. Its mild DENGUE-like symptoms include fever, rash, headaches and ARTHRALGIA. The viral infection during pregnancy, in rare cases, is associated with congenital brain and ocular abnormalities, called Congenital Zika Syndrome, including MICROCEPHALY and may also lead to GUILLAIN-BARRE SYNDROME.		02.2510
Cirrhosis
[description not available]		02.1510
Sclerosis, Systemic
[description not available]		02.1510
Fibrosis
Any pathological condition where fibrous connective tissue invades any organ, usually as a consequence of inflammation or other injury.		02.1510
Scleroderma, Systemic
A chronic multi-system disorder of CONNECTIVE TISSUE. It is characterized by SCLEROSIS in the SKIN, the LUNGS, the HEART, the GASTROINTESTINAL TRACT, the KIDNEYS, and the MUSCULOSKELETAL SYSTEM. Other important features include diseased small BLOOD VESSELS and AUTOANTIBODIES. The disorder is named for its most prominent feature (hard skin), and classified into subsets by the extent of skin thickening: LIMITED SCLERODERMA and DIFFUSE SCLERODERMA.		02.1510